Endothelial Cells Immune-Related Genes Risk Signature Correlated With Tumor Immune Microenvironment Predicts Therapeutic Response and Prognosis in Glioblastoma

Glioblastoma (GBM) is the most common and aggressive primary tumor of the central nervous system with high recurrence and extremely poor prognosis. Multiple recent studies have indicated a pivotal correlation between GBM prognosis and immune-related risk signature. Nevertheless, the potential value of endothelial cells (ECs) immune-related genes (EIRGs) in prognosis, immune infiltration, and their correlation with therapeutic response to immunotherapy and TMZ chemotherapy remain obscure, especially in GBM. Here, we screened out 11 EIRGs after intersecting the identified 59 GBM ECs related prognostic genes and the identified 438 immune-related prognostic genes. A prognostic-related 6-EIRGs signature was established through univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) Cox regression analysis, and patients in the high-risk group were significantly worse overall survival (OS) compared to those in the low-risk group. Additionally, univariate and multivariate Cox regression analysis confirmed that risk score was an independent predictor of OS in patients with GBM. The nomogram which comprised age, gender, IDH mutation status, radiation therapy, and risk score yielded a strong predictive ability of 0.5-, 1-, and 2-year OS for GBM patients. Our results demonstrate that the EIRGs signature, which is associated with immune cell infiltration, may play a regulatory role in the immunobiological process of TIME. Prognostic-related 6-EIRGs signature is a promising classification index for predicting the drug sensitivity to immunotherapy and TMZ chemotherapy, suggesting that EIRGs signature may serve as a biomarker to stratify patients who will benefit from immunotherapy and chemotherapy.